, BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas . Am J Pathol 2010 ; 177 : 1611 – 1617 . 10.2353/ajpath.2010.100212 20802181 32. Cheasley D , Nigam A , Zethoven M , Genomic analysis of low-grade serous
Search Results
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
Featured Updates to the NCCN Guidelines
Craig Horbinski, Louis Burt Nabors, Jana Portnow, Joachim Baehring, Ankush Bhatia, Orin Bloch, Steven Brem, Nicholas Butowski, Donald M. Cannon, Samuel Chao, Milan G. Chheda, Andrew J. Fabiano, Peter Forsyth, Pierre Gigilio, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ryan Merrell, Maciej M. Mrugala, Seema Nagpal, Lucien A. Nedzi, Kathryn Nevel, Phioanh L. Nghiemphu, Ian Parney, Toral R. Patel, Katherine Peters, Vinay K. Puduvalli, Jason Rockhill, Chad Rusthoven, Nicole Shonka, Lode J. Swinnen, Stephanie Weiss, Patrick Yung Wen, Nicole E. Willmarth, Mary Anne Bergman, and Susan Darlow
, with biology and outcome in pilocytic astrocytomas . Acta Neuropathol 2010 ; 119 : 641 – 649 . 20044755 61. Mistry M , Zhukova N , Merico D , BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido-Laguna, Jean L. Grem, Sarah E. Hoffe, Joleen Hubbard, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, Kristina M. Gregory, and Lisa A. Gurski
gastroesophageal cancers and CRC. Though BRAF mutations occur at a similar rate as seen in CRC, only 10% of BRAF -mutant SBAs have a V600E alteration, compared with >70% in BRAF -mutant CRC. 34 Importantly, human epidermal growth factor receptor 2 (HER2
Chandan Kumar-Sinha and Vaibhav Sahai
MET and CCND1 amplification in HCC. 3 , 4 Similar actionable subsets in BTC include FGFR2 rearrangements, IDH1/2 and BRAF mutations in iCCAs, 5 – 8 and RAS/RTK gene aberrations, such as HER2 amplification in extrahepatic CCA and GBC. 8
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Featured Updates to the NCCN Guidelines
John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh
2016 ; 13 : 473 – 486 . 27141885 10.1038/nrclinonc.2016.58 17. Robert C , Long GV , Brady B , . Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med 2015 ; 372 : 320 – 330 . 25399552 10.1056/NEJMoa1412082 18
Joshua K. Sabari, John V. Heymach, and Beth Sandy
. Negrao MV , Skoulidis F , Montesion M , BRAF mutations are associated with increased benefit from PD1/PDL1 blockade compared with other oncogenic drivers in non-small cell lung cancer . J Thorac Oncol 2019 ; 14 ( Suppl 10 ): S257 – 258 . 10
Louis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, Joachim Baehring, Henry Brem, Steven Brem, Nicholas Butowski, Jian L. Campian, Stephen W. Clark, Andrew J. Fabiano, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Craig Horbinski, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, Ian Robins, Jason Rockhill, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Lode J. Swinnen, Stephanie Weiss, Patrick Yung Wen, Nicole E. Willmarth, Mary Anne Bergman, and Susan D. Darlow
-active systemic agents; multidisciplinary evaluation is encouraged. In patients with systemic cancers with options for CNS-active systemic therapies, (eg, ALK or EGFR mutations in NSCLC; BRAF mutations in metastatic melanoma), upfront systemic therapy alone may
George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent, and Jeffrey D. Wayne
in this particular setting to be helpful in discriminating between KIT-negative GISTs and other gastrointestinal mesenchymal lesions. 28 – 30 BRAF mutations have also been reported in a small subset of intestinal high-risk GISTs (imatinibnaive or
Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh
, as well, and can give rise to noncutaneous melanomas on mucosal membranes, the uveal tract of the eye, or leptomeninges. 20 In an analysis of 102 primary melanomas, the non-CSD subtype was found to have the highest proportion of BRAF mutations (56
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho
growth factor receptor mutations in non-small cell lung cancer and BRAF mutations in metastatic melanoma), targeted therapy in neurologically asymptomatic patients with brain metastases is considered reasonable before administration of RT. Patients
